Neisseria Meningitidis Serogroup C Conjugate Vaccine
This vaccine provides active immunization against Neisseria meningitidis serogroup C, a bacterium that can cause serious and potentially life-threatening infections such as meningitis and septicemia. The vaccine contains capsular polysaccharides from serogroup C conjugated to diphtheria toxoid protein, which enhances the immune response and enables effective protection even in young children. It is primarily used in national immunization programs and for travelers to regions where serogroup C meningococcal disease is endemic.
A conjugate vaccine that protects against meningococcal disease caused by Neisseria meningitidis serogroup C by using diphtheria toxoid to enhance immune response.
Key facts at a glance
- RxNorm
- 797631
- Generic
- Neisseria Meningitidis Serogroup C Capsular Polysaccharide Diphtheria Toxoid Protein Conjugate Vaccine
- Class
- unclassified
- Brands
- Menactra
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe, injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C, including meningitis and meningococcemia. Recommended for infants, children, adolescents, and travelers to or residents of endemic areas.
The vaccine contains capsular polysaccharide antigens from N. meningitidis serogroup C that are chemically conjugated to diphtheria toxoid protein carrier. This conjugation converts the T-cell independent polysaccharide antigen into a T-cell dependent antigen, producing stronger and more durable immune responses, particularly in young children whose immune systems cannot respond effectively to polysaccharide antigens alone.
Contraindicated in individuals with known hypersensitivity to any vaccine component. Common adverse reactions include injection site pain, redness, and swelling; fever and irritability may occur in infants. Not effective against other meningococcal serogroups. Should be administered with appropriate precautions in individuals with bleeding disorders.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 29, 2026. · Read our editorial policy